4.6 Article

The Association of C-Reactive Protein and CRP Genotype with Coronary Heart Disease: Findings from Five Studies with 4,610 Cases amongst 18,637 Participants

期刊

PLOS ONE
卷 3, 期 8, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0003011

关键词

-

资金

  1. (UK) Department of Health (DOH) [PHCSA03]
  2. British Heart Foundation (BHF) [FS/05/065]
  3. Medical Research Council (MRC) of the United Kingdom [G9824960, G0601625]
  4. Health and Safety Executive
  5. National Heart Lung and Blood Institute, US, NIH [HL36310]
  6. National Institute on Aging, US, NIH [AG13196]
  7. Agency for Health Care Policy Research [HS06516]
  8. John D and Catherine T MacArthur Foundation Research Networks on Successful Midlife Development and Socio-economic Status and Health
  9. National Health and Medical Research Council of Australia [279408/379600, 458505]
  10. Academy of Finland [117604, 124327, 124332]
  11. ESRC [ES/G007438/1] Funding Source: UKRI
  12. MRC [G0600705, G0601625] Funding Source: UKRI
  13. British Heart Foundation [RG/07/008/23674] Funding Source: researchfish
  14. Economic and Social Research Council [ES/G007438/1] Funding Source: researchfish
  15. Medical Research Council [G19/35, G0600705, G8802774, G0100222, G0601625] Funding Source: researchfish
  16. Academy of Finland (AKA) [124327, 124327] Funding Source: Academy of Finland (AKA)

向作者/读者索取更多资源

Background: It is unclear whether C-reactive protein (CRP) is causally related to coronary heart disease (CHD). Genetic variants that are known to be associated with CRP levels can be used to provide causal inference of the effect of CRP on CHD. Our objective was to examine the association between CRP genetic variant +1444C>T (rs1130864) and CHD risk in the largest study to date of this association. Methods and Results: We estimated the association of CRP genetic variant +1444C>T (rs1130864) with CRP levels and with CHD in five studies and then pooled these analyses (N= 18,637 participants amongst whom there were 4,610 cases). CRP was associated with potential confounding factors (socioeconomic position, physical activity, smoking and body mass) whereas genotype (rs1130864) was not associated with these confounders. The pooled odds ratio of CHD per doubling of circulating CRP level after adjustment for age and sex was 1.13 (95% CI: 1.06, 1.21), and after further adjustment for confounding factors it was 1.07 (95% CI: 1.02, 1.13). Genotype (rs1130864) was associated with circulating CRP; the pooled ratio of geometric means of CRP level among individuals with the TT genotype compared to those with the CT/CC genotype was 1.21 (95% CI: 1.15, 1.28) and the pooled ratio of geometric means of CRP level per additional T allele was 1.14 (95% CI: 1.11, 1.18), with no strong evidence in either analyses of between study heterogeneity (I-2 = 0%, p>0.9 for both analyses). There was no association of genotype (rs1130864) with CHD: pooled odds ratio 1.01 (95% CI: 0.88, 1.16) comparing individuals with TT genotype to those with CT/CC genotype and 0.96 (95% CI: 0.90, 1.03) per additional T allele (I-2<7.5%, p. 0.6 for both meta-analyses). An instrumental variables analysis (in which the proportion of CRP levels explained by rs1130864 was related to CHD) suggested that circulating CRP was not associated with CHD: the odds ratio for a doubling of CRP level was 1.04 (95% CI: 0.61, 1.80). Conclusions: We found no association of a genetic variant, which is known to be related to CRP levels, (rs1130864) and having CHD. These findings do not support a causal association between circulating CRP and CHD risk, but very large, extended, genetic association studies would be required to rule this out.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据